AI-generated summary
The authors report a phase I trial in which 22 patients with chronic wounds received 405 nm blue light at 20, 60, or 100 J/cm² three times weekly for two weeks. Most participants had only mild skin reactions, and one developed a Grade 2 blister that could not be excluded as treatment related. The authors concluded the light was generally well tolerated and considered safe in this small cohort, with further efficacy testing needed.
- Participants
- 22
- Who or what was studied
- Twenty-two patients with chronic wounds
- Wavelengths
- 405 nm
- Limits stated in the abstract
- The abstract describes a small cohort, a single Grade 2 reaction that could not be excluded as treatment related, and does not establish antimicrobial or healing benefit.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 405 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Fluence, Dose, Photobiomodulation, GRADE, Adverse event, Wound healing. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.